Let’s Get Started
There are several options that may help you afford your Genentech medicine. Answer a few simple questions to find out which one might be right for you.
You Might Qualify for a Referral to the HEMLIBRA Co-pay Program
HEMLIBRA Access Solutions can refer you to the HEMLIBRA Co-pay Program. It can help you with the out-of-pocket costs of your Genentech medicine, if you’re eligible.*
*In order to be eligible for the HEMLIBRA Co-pay Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit HEMLIBRACopay.com for the full list of terms and conditions.
You Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
If you need help with your co-pay for your Genentech medicine, we can refer you to an independent co-pay assistance foundation.*
*Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
You Might Qualify for a Referral to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*
*If you have health insurance coverage for your medicine, you must have already tried other types of patient assistance to qualify for free Genentech medicine from the Genentech Patient Foundation. This includes the HEMLIBRA Co-pay Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance or your insurance does not cover your medicine, you must meet different financial criteria.
Important Safety Information & Indication
What it Treats
What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.
How should I use HEMLIBRA?
- Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.
- You may continue prophylactic use of factor VIII for the first week of HEMLIBRA prophylaxis.
What should I know about lab monitoring?
HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.
The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.
These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.